Overview Financials News + Filings Key Docs Charts Transactions Holdings Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
Quarterly results
Acq. announced
Director departure
Appointed director
CC transcript
Notes have priced
Inv. presentation
|
|
LIGAND PHARMACEUTICALS INC (LGND)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 02/11/2020 |
8-K
| Quarterly results |
| 01/26/2011 |
8-K
| Form 8-K - Current report |
| 10/07/2010 |
8-K
| Form 8-K - Current report |
| 08/04/2010 |
8-K
| Form 8-K - Current report |
| 01/28/2010 |
8-K
| Form 8-K - Current report |
| 12/24/2009 |
8-K
| Form 8-K - Current report |
| 10/28/2009 |
8-K
| Form 8-K - Current report |
| 08/24/2009 |
8-K
| Acquisition/merger/asset purchase announced|
Docs:
|
"Agreement and Plan of Merger, by and among Ligand Pharmaceuticals Incorporated, Neurogen Corporation, and Neon Signal, LLC",
"Form of Aplindore Contingent Value Rights Agreement",
"Form of H3 Contingent Value Rights Agreement",
"Form of Merck Contingent Value Rights Agreement",
"Form of Real Estate Contingent Value Rights Agreement",
"Form of Voting Agreement, (as to first two persons) or August 22, 2009 (as to last seven persons), entered into with Ligand Pharmaceuticals Incorporated by each of Warburg Pincus Private Equity VIII, L.P., Stephen R. Davis, Julian C. Baker, Baker/Tisch Investments, L.P., Baker Bros. Investments, L.P., Baker Bros. Investments II, L.P., Baker Biotech Fund I, L.P., Baker Brothers Life Sciences, L.P. and FBB Associates",
"Ligand to Acquire Neurogen for Stock and Contingent Value Rights Acquisition Provides Ligand a Fully Funded Partnership, Research Assets and Cash" |
|
| 12/24/2008 |
8-K
| Form 8-K - Current report |
| 09/26/2008 |
8-K
| Form 8-K - Current report |
| 01/05/2007 |
8-K
| Form 8-K - Current report |
| 10/31/2006 |
8-K
| Form 8-K - Current report |
| 09/11/2006 |
8-K
| Form 8-K - Current report |
| 09/11/2006 |
8-K
| Form 8-K - Current report |
|
|